GIPR Antagonist

Advertisement

cGxPJobs Banner

Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687

COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...

By cGxPwire Editor
July 29, 2026

Read More

Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity

COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...

By cGxPwire Editor
June 8, 2026

Read More

Advertisement

cGxPJobs

Directory